AstraZeneca, through its exclusive licensing agreement with Eccogene, is advancing the development of ECC5004, a potential oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for obesity treatment. Early data from clinical trials presented at ObesityWeek 2024 suggests ECC5004 exhibits a favorable safety profile, has the potential for once-daily dosing, and may be administered with or without food. This promising early data positions AstraZeneca to be a potential contender in the competitive weight loss market.